Sunday - July 6, 2025
IMBRUVICA (ibrutinib) Receives Positive CHMP Opinion for the Treatment of Patients With Previously Untreated Mantle Cell Lymphoma Who Would Be Eligible for Autologous Stem Cell Transplant
June 21, 2025
RARITAN, New Jersey, June 21 -- Johnson and Johnson Innovative Medicine (formerly the Janssen Pharmaceutical Companies of Johnson and Johnson) issued the following news release:

* * *

IMBRUVICA (ibrutinib) receives positive CHMP opinion for the treatment of patients with previously untreated mantle cell lymphoma (MCL) who would be eligible for autologous stem cell transplant

Pending the European Commission final decision, regimen offers a new standard of ca . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Name:
What's your
Affiliation		 Government Newspaper / Media Business
Public Policy Individual / Student Educators
Email:
Phone:
Organization, if any:
State/Country you are in:
Additonal questions
or comments:

Click here for more information about our products

Click here for more information about our products